{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T20:10:23Z","timestamp":1728850223237},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62172213","81972478","61872183"],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,19]]},"abstract":"Abstract<\/jats:title>Drug resistance is one of principal limiting factors for cancer treatment. Several mechanisms, especially mutation, have been validated to implicate in drug resistance. In addition, drug resistance is heterogeneous, which makes an urgent need to explore the personalized driver genes of drug resistance. Here, we proposed an approach DRdriver to identify drug resistance driver genes in individual-specific network of resistant patients. First, we identified the differential mutations for each resistant patient. Next, the individual-specific network, which included the genes with differential mutations and their targets, was constructed. Then, the genetic algorithm was utilized to identify the drug resistance driver genes, which regulated the most differentially expressed genes and the least non-differentially expressed genes. In total, we identified 1202 drug resistance driver genes for 8 cancer types and 10 drugs. We also demonstrated that the identified driver genes were mutated more frequently than other genes and tended to be associated with the development of cancer and drug resistance. Based on the mutational signatures of all driver genes and enriched pathways of driver genes in brain lower grade glioma treated by temozolomide, the drug resistance subtypes were identified. Additionally, the subtypes showed great diversity in epithelial\u2013mesenchyme transition, DNA damage repair and tumor mutation burden. In summary, this study developed a method DRdriver for identifying personalized drug resistance driver genes, which provides a framework for unlocking the molecular mechanism and heterogeneity of drug resistance.<\/jats:p>","DOI":"10.1093\/bib\/bbad066","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T12:54:48Z","timestamp":1677934488000},"source":"Crossref","is-referenced-by-count":1,"title":["DRdriver: identifying drug resistance driver genes using individual-specific gene regulatory network"],"prefix":"10.1093","volume":"24","author":[{"given":"Yu-e","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics , Nanjing 211106 , China"}]},{"given":"Shunheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics , Nanjing 211106 , China"}]},{"given":"Haizhou","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics , Nanjing 211106 , China"}]},{"given":"Xu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics , Nanjing 211106 , China"}]},{"given":"Mengqin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics , Nanjing 211106 , China"}]},{"given":"Fei","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics , Nanjing 211106 , China"}]},{"given":"Sina","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics , Nanjing 211106 , China"}]},{"given":"Jiahao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics , Nanjing 211106 , China"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, Southeast University , Nanjing 210009 , China"}]},{"ORCID":"http:\/\/orcid.org\/0000-0003-1591-4721","authenticated-orcid":false,"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics , Nanjing 211106 , China"}]}],"member":"286","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"issue":"10","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.trecan.2018.01.001","article-title":"The genetic\/non-genetic duality of drug 'resistance' in cancer","volume":"4","author":"Salgia","year":"2018","journal-title":"Trends Cancer"},{"issue":"10","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","article-title":"The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","article-title":"A convergence-based framework for cancer drug resistance","volume":"33","author":"Konieczkowski","year":"2018","journal-title":"Cancer Cell"},{"key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.lungcan.2017.09.005","article-title":"Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs","volume":"113","author":"Lee","year":"2017","journal-title":"Lung Cancer"},{"issue":"1","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"9","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1101\/gr.221218.117","article-title":"HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology","volume":"27","author":"Shrestha","year":"2017","journal-title":"Genome Res"},{"issue":"7","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-014-0056-8","article-title":"DawnRank: discovering personalized driver genes in cancer","volume":"6","author":"Hou","year":"2014","journal-title":"Genome Med"},{"issue":"6","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/bioinformatics\/btz815","article-title":"PRODIGY: personalized prioritization of driver genes","volume":"36","author":"Dinstag","year":"2020","journal-title":"Bioinformatics"},{"issue":"7","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/nar\/gku1393","article-title":"Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles","volume":"43","author":"Bertrand","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/bioinformatics\/bty006","article-title":"Discovering personalized driver mutation profiles of single samples in cancer by network control strategy","volume":"34","author":"Guo","year":"2018","journal-title":"Bioinformatics"},{"issue":"1","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/s41467-019-10215-y","article-title":"Optimal control nodes in disease-perturbed networks as targets for combination therapy","volume":"10","author":"Hu","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"2023032810295542800_","first-page":"237","article-title":"CDRgator: an integrative navigator of cancer drug resistance gene signatures","volume":"42","author":"Jang","year":"2019","journal-title":"Mol Cells"},{"issue":"4","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ygeno.2012.11.009","article-title":"Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line","volume":"101","author":"AbuHammad","year":"2013","journal-title":"Genomics"},{"issue":"7693","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"9","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.cell.2021.03.030","article-title":"Synthetic lethality-mediated precision oncology via the tumor transcriptome","volume":"184","author":"Lee","year":"2021","journal-title":"Cell"},{"issue":"1","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1471-2105-11-367","article-title":"A flexible R package for nonnegative matrix factorization","volume":"11","author":"Gaujoux","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"687975","DOI":"10.3389\/fimmu.2021.687975","article-title":"IOBR: multi-omics Immuno-oncology biological research to decode tumor microenvironment and signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/nmeth.2651","article-title":"Network-based stratification of tumor mutations","volume":"10","author":"Hofree","year":"2013","journal-title":"Nat Methods"},{"issue":"11","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","article-title":"The COSMIC cancer gene census: describing genetic dysfunction across all human cancers","volume":"18","author":"Sondka","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3389\/fonc.2019.00631","article-title":"Five Technologies for Detecting the EGFR T790M mutation in the circulating cell-free DNA of patients with non-small cell lung cancer: a comparison","volume":"9","author":"Chen","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12885-021-07884-8","article-title":"Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer","volume":"21","author":"Araujo","year":"2021","journal-title":"BMC Cancer"},{"issue":"7457","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"Database issue","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"D901","DOI":"10.1093\/nar\/gkm958","article-title":"DrugBank: a knowledgebase for drugs, drug actions and drug targets","volume":"36","author":"Wishart","year":"2008","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13059-020-1940-8","article-title":"Systematic functional identification of cancer multi-drug resistance genes","volume":"21","author":"Lau","year":"2020","journal-title":"Genome Biol"},{"issue":"12","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jgg.2019.11.010","article-title":"dbEMT 2.0: an updated database for epithelial-mesenchymal transition genes with experimentally verified information and precalculated regulation information for cancer metastasis","volume":"46","author":"Zhao","year":"2019","journal-title":"J Genet Genomics"},{"issue":"9","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"13349","DOI":"10.18632\/aging.202962","article-title":"Emerging roles of nucleotide metabolism in cancer development: progress and prospect","volume":"13","author":"Ma","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3892\/ijmm.2013.1302","article-title":"Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes","volume":"31","author":"Pospisilova","year":"2013","journal-title":"Int J Mol Med"},{"issue":"1638","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"20130109","DOI":"10.1098\/rstb.2013.0109","article-title":"Ion channels and transporters in the development of drug resistance in cancer cells","volume":"369","author":"Hoffmann","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1\u20132","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2119\/molmed.2010.00062","article-title":"Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy","volume":"17","author":"Ulasov","year":"2011","journal-title":"Mol Med"},{"issue":"10","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-14-0011","article-title":"Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells","volume":"13","author":"Munoz","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"e1009557","DOI":"10.1371\/journal.pgen.1009557","article-title":"Copy number signature analysis tool and its application in prostate cancer reveals distinct mutational processes and clinical outcomes","volume":"17","author":"Wang","year":"2021","journal-title":"PLoS Genet"},{"issue":"11","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/bioinformatics\/btaa895","article-title":"Sigflow: an automated and comprehensive pipeline for cancer genome mutational signature analysis","volume":"37","author":"Wang","year":"2021","journal-title":"Bioinformatics"},{"issue":"Suppl_1","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"i154","DOI":"10.1093\/bioinformatics\/btaa473","article-title":"Mutational signature learning with supervised negative binomial non-negative matrix factorization","volume":"36","author":"Lyu","year":"2020","journal-title":"Bioinformatics"},{"issue":"5","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1101\/gr.226845.117","article-title":"Mutational signatures of DNA mismatch repair deficiency in C. elegans and human cancers","volume":"28","author":"Meier","year":"2018","journal-title":"Genome Res"},{"issue":"1","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1038\/s41467-019-12594-8","article-title":"5-Fluorouracil treatment induces characteristic T>G mutations in human cancer","volume":"10","author":"Christensen","year":"2019","journal-title":"Nat Commun"},{"issue":"12 Pt 1","key":"2023032810295542800_","first-page":"5940","article-title":"Smoking and lung cancer: an overview","volume":"44","author":"Loeb","year":"1984","journal-title":"Cancer Res"},{"issue":"1","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1011-1344(97)00029-8","article-title":"Ultraviolet radiation and skin cancer of humans","volume":"40","author":"Urbach","year":"1997","journal-title":"J Photochem Photobiol B"},{"issue":"5","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"2023032810295542800_","article-title":"The importance of Ras in drug resistance in cancer","volume":"179","author":"Healy","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"5","key":"2023032810295542800_","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050048","article-title":"Targeting intracellular calcium Signaling ([Ca(2+)]i) to overcome acquired multidrug resistance of cancer cells: a mini-overview","volume":"9","author":"Busselberg","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13059-020-1951-5","article-title":"Mutational signatures: experimental design and analytical framework","volume":"21","author":"Koh","year":"2020","journal-title":"Genome Biol"},{"issue":"1","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"2023032810295542800_","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab260","article-title":"oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data","volume":"22","author":"Maeser","year":"2021","journal-title":"Brief Bioinform"},{"issue":"2","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/cncr.31834","article-title":"On high-risk, low-grade glioma: what distinguishes high from low?","volume":"125","author":"Geurts","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41419-022-04751-7","article-title":"Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression","volume":"13","author":"Hanisch","year":"2022","journal-title":"Cell Death Dis"},{"issue":"5","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1535-7163.MCT-05-0533","article-title":"Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275","volume":"5","author":"Eyupoglu","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"120176","DOI":"10.1016\/j.lfs.2021.120176","article-title":"A heat shock protein 90 inhibitor reduces oncoprotein expression and induces cell death in heterogeneous glioblastoma cells with EGFR, PDGFRA, CDK4, and NF1 aberrations","volume":"288","author":"Ho","year":"2022","journal-title":"Life Sci"},{"issue":"35","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1038\/s41388-018-0304-2","article-title":"E-cadherin in contact inhibition and cancer","volume":"37","author":"Mendonsa","year":"2018","journal-title":"Oncogene"},{"key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"110434","DOI":"10.1016\/j.biopha.2020.110434","article-title":"Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-beta and paclitaxel in A549 cells","volume":"129","author":"Bacon","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","article-title":"New insights into checkpoint kinase 1 in the DNA damage response signaling network","volume":"16","author":"Dai","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4161\/cbt.23626","article-title":"Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells","volume":"14","author":"Gandhi","year":"2013","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/bib\/bbv068","article-title":"Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes","volume":"17","author":"Cheng","year":"2016","journal-title":"Brief Bioinform"},{"issue":"50","key":"2023032810295542800_","doi-asserted-by":"crossref","first-page":"14330","DOI":"10.1073\/pnas.1616440113","article-title":"Evaluating the evaluation of cancer driver genes","volume":"113","author":"Tokheim","year":"2016","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/24\/2\/bbad066\/49666053\/bbad066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/24\/2\/bbad066\/49666053\/bbad066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T19:37:33Z","timestamp":1728848253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbad066\/7068950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbad066","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"type":"print","value":"1467-5463"},{"type":"electronic","value":"1477-4054"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2023,3]]}}}